The proof-of-concept on MyD88-targeted therapeutic approach in controlling inflammatory diseases has been validated, and even first phase clinical trial against COPD was proved to be successful [51]; reviewed by Padova et al.]. This evidence concerns the gene MYD88 and chronic obstructive pulmonary disease.